ArticleAbdominal radiology (New York)2026
Assessing the malignancy rate of adrenal nodules in patients with a history of cancer: factors associated with adrenal metastases.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine malignancy rate of adrenal nodules in patients with a history of cancer and identify factors predictive of adrenal metastases.
methodsThis Institutional Review Board-approved, retrospective study was performed 1/1/2010-12/31/2020 at an academic health system. Cancer registry data and natural language processing identified patients with a history of extra-adrenal malignancy who had undergone contrast-enhanced abdominal CT or MRI and had adrenal nodules ≥ 1 cm. A power calculation based on previously published prevalence of malignancy in adrenal nodules determined the minimum number of patients. The reference standard used for diagnosis was pathology when available, or imaging follow-up ≥ 1 year. Cancer type, presence/absence of extra-adrenal metastatic disease on index scan, and size of the adrenal nodule were extracted from the electronic health record. These factors were correlated with adrenal nodule outcome (benign or metastatic) using univariate and multivariable logistic regression analyses.
resultsThe cohort included 420 patients (219 female; mean age 71.4 years [standard deviation 11.1]). Overall metastatic adrenal nodule rate was 15.7% (66/420). Patients with extra-adrenal metastatic disease were more likely to have metastatic adrenal nodules compared to those with an isolated adrenal nodule (24.5% [37/151] vs. 10.8% [29/269]; p ≤ 0.001). Adrenal metastases were most common in patients with melanoma (50%, 10/20) and lung cancer (32%, 24/75). Metastatic rate increased with nodule size 2-4 cm (Odds Ratio [OR] 1.98) and > 4 cm (OR 3.25). In patients with an isolated adrenal nodule, primary malignancy (lung cancer: OR 10.80; melanoma: OR 32.91) and size (2-4 cm: OR 5.14, > 4 cm: OR 9.69) were associated with increased risk of metastases.
conclusionIn a cohort of patients with a history of any type of malignancy, almost 90% of isolated adrenal nodules were benign. However, a history of lung cancer, melanoma, or lesion size ≥ 2 cm significantly increased the risk of adrenal metastases.
Indexed as
Identifiers
41065829What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.